Related references
Note: Only part of the references are listed.Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Mark Lee et al.
MOLECULAR CANCER RESEARCH (2022)
MEK inhibitor resistance mechanisms and recent developments in combination trials
E. Kun et al.
CANCER TREATMENT REVIEWS (2021)
Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
Timothy M. Ullmann et al.
SURGERY (2020)
VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid cancer
Shitu Chen et al.
TRANSLATIONAL ONCOLOGY (2020)
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
Maria E. Cabanillas et al.
THYROID (2020)
Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases
Bin Xu et al.
THYROID (2020)
KRAS G12V Mutation in Acquired resistance to Combined BRAF and MEK Inhibition in Papilary Thyroid Cancer
Dwight H. Owen et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Nikita Pozdeyev et al.
CLINICAL CANCER RESEARCH (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Hezhe Lu et al.
NATURE (2017)
Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer
Nicole M. Iniguez-Ariza et al.
THYROID (2017)
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Irene M. Min et al.
CLINICAL CANCER RESEARCH (2017)
Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma
Su Yin Lim et al.
CANCER (2017)
Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma
Bin Xu et al.
ENDOCRINE PATHOLOGY (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
Hyungsoo Kim et al.
CELL REPORTS (2015)
Follicular cell-derived thyroid cancer
Henning Dralle et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Trevor E. Angell et al.
CLINICAL CANCER RESEARCH (2014)
p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
David G. McFadden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
V. Gunda et al.
CELL DEATH & DISEASE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Panayiotis Savvides et al.
THYROID (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Robert C. Smallridge et al.
THYROID (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
Cole Trapnell et al.
NATURE BIOTECHNOLOGY (2010)
Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
Rebecca E. Schweppe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype
Wilma C. G. van Staveren et al.
CANCER RESEARCH (2007)
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers
H Namba et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Antisense hTERT inhibits thyroid cancer cell growth
LS Teng et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
